Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 5,390.00
+290.00 (5.69%)
At close: Oct 1, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 266.73 billion as of October 1, 2026. Its market cap has increased by 215.46% in one year.
Market Cap
266.73B
Enterprise Value
241.45B
Revenue
24.46B
Ranking
n/a
PE Ratio
n/a
Stock Price
5,390.00
ChartMarket Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 266.73B, an increase of 271.08%. That is a compound annual growth rate of 18.39%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 30, 2026 | 266.73B | 11.89% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Curocell | 329.67B |
| Inventage Lab | 316.06B |
| HansBiomed | 300.20B |
| IMBiologics | 256.23B |
| S.Biomedics | 255.13B |
| IntoCell | 249.97B |
| curacle co.,ltd. | 218.02B |
| Kangstem Biotech | 197.51B |